Top Story

High AKR1B10 protein expression showed promising survival rates for HCC

December 18, 2014

Among a cohort of Korean patients with hepatocellular carcinoma, high aldo-keto reductase 1B10 protein expression predicted longer recurrence-free and disease-specific survival rates vs. patients with low protein expression.

Sang Yun Ha, MD, of Sungkyunkwan University School of Medicine in Korea, and colleagues used tissue microarrays to measure expression levels of aldo-keto reductase 1B10 (AKR1B10) protein in tumors of 255 patients with HCC who underwent curative hepatectomy to determine its effect on the survival of the patients during a median follow-up period of 119.8 months.

FDA approvals

FDA approves Somatuline Depot for gastroenteropancreatic neuroendocrine tumors

December 16, 2014
The FDA today approved lanreotide for treatment of patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic…
In the Journals

Normal IBI predicted OS in patients undergoing TACE for HCC

December 16, 2014
Normalization of inflammation-based index score after transarterial chemoembolization therapy among patients with hepatocellular carcinoma predicted a greater overall…
Karen Midthun, MD FDA approvals

FDA approves 9-valent HPV vaccine for certain cancers

December 10, 2014
The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of anal, cervical, vaginal…
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
In the Journals

High AKR1B10 protein expression showed promising survival rates for HCC

December 18, 2014
Among a cohort of Korean patients with hepatocellular carcinoma, high aldo-keto reductase 1B10 protein expression predicted longer recurrence-free…
FDA approvals

FDA approves Somatuline Depot for gastroenteropancreatic neuroendocrine tumors

December 16, 2014
The FDA today approved lanreotide for treatment of patients with unresectable, well- or moderately differentiated, locally advanced or metastatic…
In the Journals

Normal IBI predicted OS in patients undergoing TACE for HCC

December 16, 2014
Normalization of inflammation-based index score after transarterial chemoembolization therapy among patients with hepatocellular carcinoma predicted…
Karen Midthun, MD FDA approvals

FDA approves 9-valent HPV vaccine for certain cancers

December 10, 2014
The FDA today approved a new vaccine for the prevention of certain diseases caused by HPV that has the potential to prevent approximately 90% of…
In the Journals

Longer transplant wait times yielded higher survival rates for patients with HCC

December 10, 2014
Liver transplant recipients in the long waiting time region who underwent transplantation due to hepatocellular carcinoma had a greater survival rate…
Nucleoside analogues reduced HCC incidence among patients with HBV In the Journals

Nucleoside analogues reduced HCC incidence among patients with HBV

December 5, 2014
Patients with hepatitis B virus infection treated with long-term nucleoside analogue therapy had a decreased risk for developing hepatitis B virus…
In the Journals

Ziv-aflibercept plus FOLFIRI extended OS in metastatic colorectal cancer

December 5, 2014
The addition of ziv-aflibercept to FOLFIRI chemotherapy was associated with durable improvements in survival among patients with metastatic…
FDA News

FDA fast tracks necuparanib for metastatic pancreatic cancer

December 2, 2014
The FDA granted fast track designation to the investigation of necuparanib for treatment of patients with metastatic pancreatic cancer, according to…
In the Journals

Olaparib induced tumor response in patients with germline BRCA1/BRCA2 mutations

December 1, 2014
Olaparib monotherapy induced responses across tumor types in patients with germline BRCA1 or BRCA2 mutations, according to results of a multicenter…
Inflammation-based scores failed to predict HCC recurrence after liver transplant In the Journals

Inflammation-based scores failed to predict HCC recurrence after liver transplant

November 28, 2014
Multiple inflammation scores were not associated with an increased risk for hepatocellular carcinoma recurrence after liver transplantation…
More Headlines »
morganatic-roan